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Abstract
Introduction: There are limited treatment options for people with schizophrenia with cytochrome P450 2D6
ultrarapid metabolizer status who do not respond to amisulpride.
Furthermore, the literature does not provide evidence-based guidelines for this particular constellation.
Case presentation: We report the case of a 50-year-old Caucasian female patient with schizophrenia and
cytochrome P450 2D6 ultrarapid metabolizer status who experienced an insufficient antipsychotic effect with
amisulpride. She was successfully treated with melperone-augmented haloperidol.
Conclusion: This report yields melperone-augmented haloperidol as a possible pharmacological strategy in the
described situation. In addition, our observations support the available evidence for the potential of melperone to
act as an inhibitor of cytochrome P450 2D6.
Introduction
Enhancing the effect of a pharmacological agent by add-
ing on another drug is commonly called augmentation.
One possible augmentation strategy is via induction of
pharmacokinetic interactions. Here the added agent
interacts with enzymes of the cytochrome P450 system
(CYP) that is important for the hepatic metabolization
of numerous drugs. Thus, utilizing the pharmacokinetic
properties of a particular agent allows its application as
a specific inhibitor or inductor of metabolic pathways of
the drug to be enhanced. This can, for example, allow
decreased doses to result in sufficient plasma level con-
centrations. Within the CYP family, CYP2D6 is a poly-
morphic enzyme that is of relevance for the metabolism
of most typical antipsychotics [1]. There are more than
100 genetic variants (catalogued by the website: http://
www.cypalleles.ki.se). Out of these, there are four phe-
notypes (poor, intermediate, extensive and ultrarapid
metabolizers) that are associated with different enzyme
activities and whose incidence vary among ethnic groups
[2]. Ultrarapid metabolizers (UM) are people with mark-
edly elevated enzyme activity; there are estimated to be
between 0.5% and 7% UMs within the Caucasian popu-
lation [3,4]. Patients with intractable schizophrenia and
CYP2D6 UM status can benefit from a treatment with
the antipsychotic amisulpride, which is almost comple-
tely eliminated through the renal pathway. Therapeutic
alternatives for non-responders under amisulpride are
limited and evidence-based guidelines regarding this
particular treatment situation are lacking. In the follow-
ing, we report successful treatment with melperone-aug-
mented haloperidol in a patient with schizophrenia and
UM status.
Case presentation
Our patient was a 50-year-old Caucasian woman, a non-
smoker, with a 20-year history of undifferentiated schizo-
phrenia, according to the Diagnostic and Statistical Man-
ual, Fourth Edition, Text Revision criteria. She was
admitted to our clinic for acute psychotic exacerbation.
Due to numerous treatments in our clinic over the last
10 years, our patient was well known and the diagnosis of
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tic episodes and unremarkable somatic examination,
including analysis of her cerebrospinal fluid, an electro-
encephalogram and magnetic resonance imaging of her
brain.
Initially, she presented with auditory hallucinations, dis-
organized speech, inappropriate affect with an occasionally
euphoric mood, grossly disorganized behavior and excit-
ability. Prior to this hospital admission, her antipsychotic
treatment (retard preparation of quetiapine, 700 mg per
day) was taken irregularly. Further, impaired glucose toler-
ance due to adiposity and metabolic syndrome (weight
102.8 kg, height 156 cm, body mass index 42.2 kg/m
2)w a s
treated with metformin (500 mg per day). We first contin-
ued quetiapine for seven days without amelioration of the
clinical situation. In view of sufficient quetiapine serum
levels (854 ng/mL) and remarkable obesity, a treatment
trial with an increased dosage of quetiapine was not per-
formed. While tapering off quetiapine, we administered
amisulpride and titrated up to a daily dosage of 1200 mg
within five days. No substantial improvement was achieved
with this regimen within 21 days.
Phenotypic testing in our patient with dextromethor-
phan (DM) revealed CYP2D6 UM status (DM < 5 ng/mL;
dextrorphan (DO) 640 ng/mL; DM/DO ratio: < 0.008;
3-methoxymorphinan (MM) < 5 ng/mL; 3-hydroxymor-
phinan (HM) 24 ng/mL; MM/HM ratio: 0.21), which also
explained recent ineffective treatment attempts with ris-
peridone (up to 8 mg per day) and haloperidol-decanoate
(up to 150 mg per injection). This phenotypic testing was
performed by taking a blood sample (120 mL) exactly one
hour after the oral application of 40 mL NeoTussan
®
cough syrup (111 mg dextromethorphan per 100 g sus-
pension (Novartis Consumer Health GmbH; city: Munich;
state: Bavaria; country: Germany). Her blood was analyzed
for metabolites of DM and MM, which are substrates of
CYP2D6. The DM to DO and MM to HM ratios are sur-
rogate parameters for CYP2D6 activity.
Following the reduction of amisulpride down to 800 mg
per day, haloperidol (10 mg per day) was applied as an
additional antipsychotic. Simultaneously, trazodone (100
mg per day) was added on in order to augment the halo-
peridol by CYP2D6 inhibition, but did not show significant
clinical success in the next days. Gradual escalation of
haloperidol and trazodone doses over a period of one
month did not obtain amelioration of the psychotic phe-
nomena. At that time, haloperidol plasma levels (current
medication: amisulpride 800 mg per day; haloperidol
15 mg per day; trazodone 200 mg per day; and metformin
500 mg per day) were at 10 ng/mL. A subsequent increase
of haloperidol up to 20 mg per day did neither improve
the clinical situation nor serum plasma levels (9 ng/mL).
Since her psychopathological findings did not change
under treatment with amisulpride and still presented as on
admission time, the antipsychotic effect of amisulpride was
evaluated to be insufficient according to the treatment
guideline for schizophrenia of the German Association for
Psychiatry, Psychotherapy and Neuroscience [5]. After dis-
continuation of trazodone and amisulpride, we adminis-
tered melperone (100 mg per day), in order to inhibit
CYP2D6, and elevated haloperidol up to 30 mg per day.
After 14 days, her haloperidol plasma levels were at 19 ng/
mL. This result was confirmed in a second test (haloperi-
dol: 20 ng/mL). In line with this, her clinical performance
improved slightly, and she demonstrated attenuation in
her auditory hallucinations, redevelopment of day struc-
ture and a marked improvement regarding behavior and
speech. Our patient was then discharged with this medica-
tion in a clearly improved clinical condition.
Discussion
There are no evidence-based guidelines in the literature
for patients with schizophrenia and CYP2D6 UM status
that do not respond to amisulpride. Our report yields
the combination of a high dose of haloperidol augmen-
ted with melperone as a possible pharmacological strat-
egy in patients under these conditions. Considering that
the patient´s haloperidol serum levels increased concur-
rently with elevated doses of haloperidol, the question
arises to what the melperone effectively contributed to
sufficient haloperidol serum levels. Though reports on
the potential of melperone as an inhibitor of CYP2D6-
dependent metabolization of psychopharmacologic
drugs are available [6,7], it is conceivable that, in our
case, sufficient haloperidol plasma levels were simply a
consequence of escalated oral haloperidol doses, and to
a lesser extent induced by melperone-mediated CYP2D6
inhibition. Discontinuation of melperone and repeated
measurements of haloperidol serum levels under the
removed influence of melperone could have provided
clarity. However, due to the unstable clinical situation
and first-time treatment success with melperone-aug-
mented haloperidol, we refrained from any modification
of the psychopharmacotherapy. Apart from that, the
combination of haloperidol and melperone was success-
ful in our patient with regard to haloperidol plasma
levels and schizophrenic target symptoms. Retrospec-
tively, the repeated modifications of psychopharma-
cotherapy in this case during a comparatively short
period of time are problematic and thus, for example,
continuation of amisulpride for a longer interval should
have been attempted.
Conclusion
We hypothesize that melperone-augmented haloperidol
can be considered as a possible treatment strategy in
patients with schizophrenia, CYP2D6 UM status and
insufficient antipsychotic effect of amisulpride.
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plasma levels under augmentation with melperone is in
line with studies that described melperone as an inhibi-
tor of CYP2D6-dependent metabolization of risperidone
[6] and venlafaxine [7].
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